Janssen Biotech and Johnson & Johnson announced pharma deals with Icahn School of Medicine at Mount Sinai to advance scientific understanding of inflammatory bowel disease and discover next generation therapeutic solutions.
Scientists from the Janssen Immunology Therapeutic Area and researchers from Mount Sinai will work on pharma deals to investigate disease triggers, identify new opportunities for therapeutic interventions and establish diagnostics to facilitate precision medicine and predictive biomarkers.
The first-of-its-kind industry and academic partnership brings together Janssen research and development capabilities with an early-stage life science investment through the Johnson & Johnson Innovation center in Boston and Mount Sinai's expertise in computational biology, and clinical and translational research in IBD as part of the pharma deals.
The pharma deals collaboration will focus on building a Molecular Interaction Network of Disease in IBD with the breadth and depth to yield high confidence therapeutic hypotheses to be tested in vitro and in vivo.
Using preclinical models, clinical study data and patient samples, a dedicated group of Janssen and Mount Sinai researchers, computational biologists and translational medicine scientists will develop clinical methodologies to test hypotheses and identify potential therapeutic candidates as part of the pharma deals.
This unique industry and academic research alliance brings together scientific and institutional resources from Mount Sinai, Janssen and Johnson & Johnson Innovation representing each organization's deep commitment and investment in transforming the treatment of IBD.
Report: Inflammatory Bowel Disease Partnering
Report: Partnering Deals and Alliances with Johnson & Johnson / Janssen
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: Current Partnering’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity